SCHEDULE: Farallon Capital Amends Agios Pharma Stake, Updates Management
Ownership Disclosure
Farallon Capital Management and its affiliates updated their beneficial ownership in Agios Pharmaceuticals, Inc. to 8.8%, reflecting internal management changes within Farallon.
Summary
- Farallon Capital Management and its affiliated entities collectively report beneficial ownership of 5,159,505 shares of Agios Pharmaceuticals, Inc. common stock.
- This represents 8.8% of the class of securities.
- The filing is an Amendment No. 4 to a previously filed Schedule 13G.
- The reporting group includes various Farallon funds, general partners, and individual managing members/managers.
- Farallon Partners, L.L.C. holds 5,046,401 shares, representing 8.7% of the class.
- Farallon Healthcare Partners Master, L.P. and Farallon Healthcare Partners (GP), L.L.C. each hold 2,928,459 shares, representing 5% of the class.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership and internal management changes within the reporting entity, Farallon Capital, with no direct positive or negative implications for Agios Pharmaceuticals' operational or financial performance.
Positives
- Continued significant institutional ownership by Farallon Capital, indicating ongoing investment interest in Agios Pharmaceuticals.
- The 8.8% stake suggests a substantial, long-term position by a sophisticated investor.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that significant institutional ownership, such as Farallon Capital's 8.8% stake in Agios Pharmaceuticals, is common in the biotechnology and pharmaceutical sectors, where long-term investment horizons and specialized expertise are often required to assess pipeline value and market potential. Such holdings can signal confidence from sophisticated investors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member/Manager of Farallon General Partner and related entities | NA | Avner A. Husen | 2026-01-01 | Became a managing member/manager, leading to beneficial ownership of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon General Partner and related entities | Richard B. Fried | NA | 2025-12-31 | Ceased to be a managing member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon General Partner and related entities | Rajiv A. Patel | NA | 2025-12-31 | Ceased to be a managing member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon General Partner and related entities | William Seybold | NA | 2025-12-31 | Ceased to be a managing member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Management Appointment | Avner A. Husen was appointed as a managing member or senior managing member of Farallon Partners, L.L.C. and a manager or senior manager of Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., and Farallon Healthcare Partners (GP), L.L.C. | 2026-01-01 | This change impacts the individuals with investment discretion over the Farallon Funds' holdings in Agios Pharmaceuticals. |
| Internal Management Departure | Richard B. Fried, Rajiv A. Patel, and William Seybold ceased their roles as managing members/managers of Farallon Partners, L.L.C. and its related general partners. | 2025-12-31 | Their departure means they are no longer deemed beneficial owners of the shares held by the Farallon Funds. |
Stakeholder Impact
- Shareholders: The filing confirms a significant, stable institutional ownership stake by Farallon Capital, which can be viewed positively as a vote of confidence from a major investor. The internal management changes within Farallon do not directly alter the overall beneficial ownership percentage in Agios.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Date of event requiring filing, also effective date for cessation of beneficial ownership for Richard B. Fried, Rajiv A. Patel, and William Seybold. |
| 2026-01-01 | Effective date for Avner A. Husen becoming a beneficial owner of shares held by Farallon Funds. |
| 2026-02-09 | Filing date of Amendment No. 4 to Schedule 13G. |
Keywords
Agios Pharmaceuticals, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Healthcare, SEC Filing, Ownership Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.